• Home
  • About
  • Recent public offerings
  • Our practice
Explore Close
Menu Close

Categories

RegulatorySPACsEventsResourceUncategorizedTrendsDealsLitigationNewsAudio

Tags

SPACsIPOUKCOVID-19SECEventsDirect ListingPublic ReadinessEU Market Abuse Regulation (MAR)European Union (EU)USAIMcorporate governancelitigationnasdaqsecuritiesresourcesclimate disclosureboard gender diversityCross Border

Archives

October 2025 September 2025 July 2025 June 2025 April 2025 March 2025
  • Home
  • About
  • Recent public offerings
  • Our practice

CapitalXchange

Legal insight for the capital markets

  • Regulatory
  • SPACs
  • Events
  • Resource
  • Uncategorized
Close
Deals

Beta Bionics on its $234.6 Million IPO

anguyencooley on October 30, 2025

Makers of the first and only fully automated bionic pancreas

Cooley advised Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, on its upsized $234.6 million initial public offering (IPO) and concurrent $17 million private placement. Partners Carlos Ramirez, Mark Weeks and Charlie Kim led the Cooley team advising Beta Bionics.

 

 

Related

Ready to HIT GO on your IPO?

Get started

Subscribe to new post notifications.

Loading

We Advised

  • Stubhub on its $800 Million IPO
    Stubhub on its $800 Million IPO
  • LB Pharmaceuticals on its $285 Million IPO
    LB Pharmaceuticals on its $285 Million IPO
  • Heartflow on its $364.2 Million Upsized IPO
    Heartflow on its $364.2 Million Upsized IPO
  • Ambiq Micro on its $110.4 Million IPO
    Ambiq Micro on its $110.4 Million IPO
  • Caris Life Sciences on its $494 Million IPO
    Caris Life Sciences on its $494 Million IPO
  • AIRO Group on its $69 Million IPO
    AIRO Group on its $69 Million IPO
  • Beta Bionics on its $234.6 Million IPO
    Beta Bionics on its $234.6 Million IPO
  • Artiva Biotherapeutics on its $167 Million IPO
    Artiva Biotherapeutics on its $167 Million IPO
  • Tempus AI on its $410.7 Million IPO
    Tempus AI on its $410.7 Million IPO
  • Life360 on its $178.5 Million IPO
    Life360 on its $178.5 Million IPO

Recent

  • Navigating the Government Shutdown: SEC Operations and Your Offering (Live Updates)
  • CapitalXchange Audio – Strategic Reincorporations With Courtney Tygesson
  • Nasdaq Revisits Listing Requirements (Again): Proposing Stricter Criteria for New and Continued Listings
  • Nasdaq Revisits Listing Requirements (Again): Proposing Simpler Paths to Going and Staying Public
  • What a Government Shutdown Means for Your IPO 

Disclaimer

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.

Previous
Artiva Biotherapeutics on its $167 Million IPO
September 11, 2024
Next
AIRO Group on its $69 Million IPO
October 30, 2025